Suppr超能文献

鼠伤寒沙门氏菌活疫苗预防雏鸡肠道定植的体内外效力。

In vitro and in vivo efficacy of a live attenuated Salmonella Typhimurium vaccine at preventing intestinal colonization in chicks.

机构信息

School of Animal and Veterinary Sciences, Roseworthy Campus, University of Adelaide, Adelaide, SA, Australia.

出版信息

Zoonoses Public Health. 2018 Sep;65(6):736-741. doi: 10.1111/zph.12479. Epub 2018 May 14.

Abstract

Vaccination of chicks with Salmonella (S.) Typhimurium aroA deletion mutants has previously been shown to inhibit intestinal colonization of wild-type S. Typhimurium strains. In Australia, Bioproperties VaxSafe™ STM1 strain is the only licensed and commercially available S. Typhimurium vaccine. This vaccine is a live attenuated aroA deletion mutant. Currently, it is recommended that the first dose of the STM1 vaccine is administered through coarse spray. It is unclear whether this mode of administration effectively permits intestinal colonization. Furthermore, it is not known whether the STM1 strain prevents or inhibits Salmonella colonization of chicks following this first dose. This study investigated both in vitro and in vivo colonization parameters. Invasiveness was assessed using an in vitro invasion assay into sections of ileum and caecum collected from day-old chicks. The S. Typhimurium definitive types (DT) 9 and 44 exhibited the greatest invasion into both intestinal segments. STM1 was invasive but was significantly less so than both isolates of S. Typhimurium. In dual and triple infections, no competitive microbial interactions between STM1 and wild-type Salmonella were observed. In vivo colonization inhibition was also tested. Vaccinated and nonvaccinated day-old chicks were challenged with S. Typhimurium DT9. Both STM1 and S. Typhimurium DT9 were found in spleen, liver, ileum, caecum and caecal contents from day 2 postinfection. No significant exclusion effect was observed in vaccinated and challenged chicks.

摘要

先前的研究表明,用沙门氏菌(S.)Typhimurium aroA 缺失突变体对雏鸡进行免疫接种可抑制野生型 S. Typhimurium 菌株的肠道定植。在澳大利亚,Bioproperties VaxSafe™ STM1 菌株是唯一获得许可并可商业获得的 S. Typhimurium 疫苗。该疫苗是一种活的减毒 aroA 缺失突变体。目前,建议首剂量的 STM1 疫苗通过粗喷雾给药。尚不清楚这种给药方式是否能有效地促进肠道定植。此外,尚不清楚 STM1 菌株在首剂量后是否能预防或抑制雏鸡的沙门氏菌定植。本研究调查了体外和体内定植参数。使用体外侵袭试验评估侵袭性,将其应用于从小鸡收集的回肠和盲肠切片中。S. Typhimurium 定型型(DT)9 和 44 对两个肠段的侵袭性最强。STM1 具有侵袭性,但显著低于两种 S. Typhimurium 分离株。在双重和三重感染中,未观察到 STM1 与野生型沙门氏菌之间存在竞争性微生物相互作用。还测试了体内定植抑制作用。接种和未接种的 1 日龄雏鸡用 S. Typhimurium DT9 进行攻毒。在感染后第 2 天,在雏鸡的脾脏、肝脏、回肠、盲肠和盲肠内容物中均发现了 STM1 和 S. Typhimurium DT9。在接种和攻毒的雏鸡中未观察到明显的排斥效应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验